BRAIN Biotech AG at a Glance
Key Player in the Bioeconomy
| Headquarter | Zwingenberg, Germany (Hesse) |
| Year of Foundation | 1993 |
| Employees | 310 (as of September 2023) |
| Revenues | 55.3 Mio Euro (Financial Year 2022/23) |
| Specialists knowledge | Biology, microbiology, biochemistry, chemistry, bioinformatics, bioprocess engineering, food technology, analytics, etc. |
| Markets | Food & Beverages, Pharma, Life Science, Environment |
| Patents | 40 active patent families with varying numbers of individual patents |
|
Services, solutions, products
|
Enzyme technology: Discover, analyze, optimize and produce enzymes on an industrial scale in a variety of microbial production organisms. Production strain development: microorganism identification; microbial strain development (non-GMO and GMO); provision of functional biomass to optimize industrial production processes. Bioprocess development: Developing production processes on a laboratory scale; process validation and sample generation; process transfer to industrial production scale (10,000 liters). Production: Large-scale production and refinement of enzymes and other proteins. |
|
Business segments
|
BioProducts: product business with specialized enzymes and other proteins BioScience: research-intensive customized solutions based on enzyme technology, microbial strain development for production, bioprocess development and natural product screening. BioIncubator: own or partner-initiated R&D projects with high value creation potential |
BRAIN Biotech AG is the parent company of the BRAIN Biotech Group. The group´s headquarter is located in Zwingenberg, South Hesse, Germany.
BRAIN Biotech AG has been listed in the Prime Standard segment of the Frankfurt Stock Exchange since February 9, 2016 (ticker symbol: BNN; securities identification number: ISIN DE0005203947/WKN 520394). The Group generated sales of EUR 55.3 million in the 2022/23 financial year.
The BRAIN Biotech Group includes (as of September 2023): AnalytiCon Discovery LLC, Biocatalysts Ltd, Biocatalysts Inc, Biosun Biochemicals Inc, WeissBioTech GmbH and Breatec B.V. (62.0 %). The companies Biocatalysts Inc., Biosun Biochemicals Inc., WeissBioTech GmbH and the investment in Breatec B.V. (62.0%) will be allocated to Biocatalysts Ltd. from October 1, 2023.